AngioSoma, Inc. is a publicly traded clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments related to endovascular interventions for peripheral artery disease (“PAD”). Liprostin™, our lead PAD treatment product candidate, successfully completed U.S. Food and Drug Administration (“FDA”) required Phase I and II clinical trials and is entering the final phase prior to approval, Phase III trials. Beyond Liprostin™, we have a robust product pipeline with existing & provisional patents, formulations, and trademarks aimed at improving the standard-of-care in treating PAD with stents, reabsorb-able stents, atherectomy catheters, and tunneling catheters.
- SOAN (Common Stock shares)
- quoted on OTC Markets’ OTC:QB
- Information sources:
- Transfer Agent
Island Stock Transfer (information on OTC Markets)
15500 Roosevelt Boulevard, Suite 301, Clearwater, FL 33760
- Legal Counsel
Sonfield & Sonfield, Attorneys at Law (information on OTC Markets)
2500 Wilcrest Drive, Suite 300, Houston, TX 77042
M&K CPAS, PLLC (information on OTC Markets)
4100 North Sam Houston Pkwy W, Suite 200-B, Houston, TX 77086
Investor Relations Contact
© 2016 by AngioSoma, Inc., all rights reserved.